在南亚区域合作联盟 (SAARC) 国家的癌症研究
M Saiful Huq1, Sandhya C Acharya2, Manish Gautam3
1Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
The Lancet. Oncology
|December 5, 2024
概括
尽管癌症发病率上升,但南亚区域合作联盟 (SAARC) 国家的癌症研究投资滞后. 加强当地研究能力对于开发适用且负担得起的癌症疗法至关重要.
科学领域:
- 在瘤学瘤学.
- 全球健康 全球健康
- 卫生政策 卫生政策
背景情况:
- 癌症是一个重大的全球健康挑战,预计在低收入和中等收入国家增加.
- 在高收入国家和南亚区域合作联盟 (SAARC) 国家之间,癌症研究投资和产出存在巨大的差异.
- 在SAARC国家癌症发病率的上升并没有与当地研究相匹配,特别是在诸如分子生物学,向治疗,免疫治疗和癌症疫苗的临床试验等先进领域.
研究的目的:
- 检查包括孟加拉国,尼泊尔,斯里兰卡,印度,巴基斯坦,阿富汗,不丹和马尔代夫在内的SAARC国家癌症研究的现状.
- 分析SAARC各国的出版率,研究基础设施,正在进行的研究以及癌症研究的局限性.
- 确定关键挑战,并提出加强该地区癌症研究能力的战略.
主要方法:
- 在SAARC国家对癌症研究的PubMed出版率的分析.
- 评估现有的研究基础设施和当前的临床试验环境.
- 审查SAARC成员国癌症研究的局限性和差异.
主要成果:
- 与高收入国家相比,癌症研究投资和产出存在重大差距.
- 局部研究有限,特别是在高级癌症治疗的临床试验中.
- 确定的主要挑战包括医疗保健获取差异,社会经济障碍以及资金和基础设施不足.
结论:
- 在SAARC国家进行的癌症研究面临着巨大的障碍,包括资金,基础设施和西方开发的指导方针的适用性.
- 加强癌症研究需要合作网络,改进设施,当地流行病学研究和开发负担得起的治疗方法.
- 政策干预和利益相关者参与对于在SAARC地区推进癌症护理至关重要.
相关概念视频
01:03Rous Sarcoma Virus (RSV) and Cancer
5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.0K
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
02:43Mouse Models of Cancer Study
5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:40Cancer Stem Cells and Tumor Maintenance
4.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.8K